Published on 11/06/2026

Understanding the Structure of PV Governance for Compliance with Schedule M

Introduction to PV Governance in Schedule M

Pharmacovigilance (PV) is a crucial component of drug safety and efficacy, particularly in the Indian pharmaceutical landscape governed by Schedule M. The PV governance framework ensures that all adverse drug reactions (ADRs) are reported, assessed, and managed effectively. This article outlines the essential elements of a PV governance committee structure, focusing on the roles of the Qualified Person for Pharmacovigilance (QPPV) and the Pharmacovigilance System Master File (PSMF).

The Role of the PV Governance Committee

The PV governance committee is responsible for overseeing the pharmacovigilance activities within an organization. This committee typically includes representatives from various departments such as Quality Assurance (QA), Regulatory Affairs, Clinical Development, and Medical Affairs. The key responsibilities of the committee include:

• Establishing and maintaining the pharmacovigilance system.
• Ensuring compliance with Schedule M and CDSCO regulations.
• Reviewing and approving SOPs related to pharmacovigilance.
• Monitoring the performance of the pharmacovigilance system.
• Facilitating training and awareness programs for staff.

Qualified Person for Pharmacovigilance (QPPV)

The QPPV plays a pivotal role in the pharmacovigilance framework. Appointed by the organization, the QPPV is responsible for:

• Ensuring the establishment and maintenance of a pharmacovigilance system that complies with regulatory requirements.
• Acting as the primary contact for regulatory authorities, including CDSCO.
• Overseeing the collection, assessment, and reporting of ADRs.
• Ensuring that all pharmacovigilance activities are documented appropriately.

Pharmacovigilance System Master File (PSMF)

The PSMF is a critical document that outlines the pharmacovigilance system in place within an organization. It serves as a comprehensive reference for regulatory authorities during inspections. Key components of the PSMF include:

• A detailed description of the pharmacovigilance system.
• Information on the QPPV and their contact details.
• Procedures for ADR reporting and management.
• Details of training programs for staff involved in pharmacovigilance.

Implementation of SOPs for PV Compliance

Standard Operating Procedures (SOPs) are essential for ensuring consistency and compliance in pharmacovigilance activities. Organizations should develop SOPs that cover:

• ADR reporting processes.
• Data entry and management in the pharmacovigilance database.
• Periodic safety update reports (PSURs) preparation.
• Risk management plans (RMPs) and their implementation.

Documentation and Inspection Readiness

Documentation is a cornerstone of pharmacovigilance compliance. Organizations must ensure that all pharmacovigilance activities are documented thoroughly and accurately. This includes:

• Maintaining records of ADR reports and follow-ups.
• Documenting training sessions and participant attendance.
• Keeping a log of all communications with regulatory authorities.

Being inspection-ready involves regular internal audits and mock inspections to identify gaps and areas for improvement.

Corrective and Preventive Actions (CAPA)

Implementing a CAPA system is vital for addressing non-compliance issues and preventing recurrence. The CAPA process should include:

• Identification of the root cause of non-compliance.
• Development of action plans to address identified issues.
• Monitoring the effectiveness of implemented actions.

Quality Assurance Integration

Integrating pharmacovigilance with quality assurance processes enhances overall compliance and safety. QA teams should be involved in:

• Reviewing pharmacovigilance SOPs and documentation.
• Conducting regular audits of the pharmacovigilance system.
• Ensuring that all pharmacovigilance activities align with quality standards.

ADR Reporting and Compliance

Adverse drug reaction reporting is a critical aspect of pharmacovigilance. Organizations must ensure timely and accurate reporting of ADRs to the CDSCO. Key steps include:

• Establishing clear reporting channels for healthcare professionals and patients.
• Training staff on the importance of ADR reporting.
• Regularly reviewing ADR reports to identify trends and safety signals.

FAQs

1. What is the role of the QPPV in pharmacovigilance?

The QPPV is responsible for ensuring that the pharmacovigilance system is compliant with regulatory requirements and acts as the primary contact for regulatory authorities.

2. How often should SOPs be reviewed in pharmacovigilance?

SOPs should be reviewed at least annually or whenever there are significant changes in regulations or internal processes.

3. What is the purpose of the PSMF?

The PSMF provides a comprehensive overview of the pharmacovigilance system and serves as a reference document during regulatory inspections.

4. How can organizations ensure inspection readiness for pharmacovigilance?

Regular internal audits, mock inspections, and thorough documentation practices are essential for maintaining inspection readiness.

5. What are the key components of a CAPA system in pharmacovigilance?

A CAPA system should include root cause analysis, action plan development, and monitoring of the effectiveness of implemented actions.

Related Resources

For more information on pharmacovigilance compliance under Schedule M, visit our Pillar Page on Schedule M Compliance.